Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RS001 in Relapsed/Refractory B-Cell Malignancies
NCT06894693Phase 1Not yet recruiting
- Sponsor
- Guangdong Ruishun Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of RS-001 in B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL), sponsored by Guangdong Ruishun Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
RS-001
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06894693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894693.